Syntekabio to hold extraordinary general meeting on business expansion plans

Syntekabio, a Korean AI-driven drug development company, announced plans to hold an extraordinary general meeting (EGM) on Jan. 23, 2025, to amend its articles of incorporation and expand its business objectives. The shareholder register will close on Dec. 20, 2024.  

The proposed amendments include adding business-to-business (B2B) data center leasing services, consulting for data center design and operations, and colocation services to the company’s objectives.  

“At the EGM, we aim to approve these additions and prioritize the early establishment of the new business,” said a Syntekabio official. The company plans to utilize its existing AI Bio Supercom Center (ABS Center) to avoid initial investment costs while meeting growing market demand.  

CEO Jung Jong-sun highlighted the strategic advantages of Syntekabio’s data center, which uses natural convection technology to address resource shortages and high demand.

The Daejeon-based ABS Center, operational since October 2023, integrates supercomputing and AI for drug discovery. The facility features approximately 5,000 high-performance supercomputers that enable the monthly discovery of over 50 novel drug candidates and perform 7,200 genomic analyses.  

Building on its infrastructure for AI-driven drug development, Syntekabio is diversifying into data center services. The company’s data center design incorporates natural convection technology inspired by African termite mounds, providing energy efficiency and a competitive edge, the company said.

Jung emphasized the strategic shift, stating, “We aim to leverage our infrastructure for broader business applications, meet market demands, and secure stable revenue. We are finalizing colocation service contracts with several clients and anticipate meaningful results soon.”